1cP-MiPLA

1cP-MiPLA, also known as 1-cyclopropanoyl-MiPLA or 1-cyclopropanoyl-N-methyl-N-isopropyllysergamide, is a presumed psychedelic drug of the lysergamide family. It is the 1-cyclopropanoyl derivative of MiPLA and is thought to be a prodrug of MiPLA. 1cP-MiPLA has been encountered as a novel designer drug online and in Japan.

Use and effects

1cP-MiPLA has been sold in the form of blotter tabs containing doses of 200μg per tab. Data on the effects of 1cP-MiPLA at different doses are not available.

Interactions

Pharmacology

1cP-MiPLA is assumed to act as a prodrug of MiPLA via deacylation. Relatedly, it is assumed to act as a serotonin receptor agonist, including of the serotonin 5-HT_2A receptor, and to be a serotonergic psychedelic.

Chemistry

Analogues

s of 1cP-MiPLA include MiPLA, 1P-MiPLA, and 1cP-AL-LAD, among others.

History

1cP-MiPLA was first encountered as a novel designer drug online in 2020 and in Japan by 2022.

Society and culture

Legal status

Canada

1cP-MiPLA is not a controlled substance in Canada as of 2025.

Russia

1cP-MiPLA is a schedule I controlled substance in Russia.

United States

1cP-MiPLA is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.